---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-171731"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:45:58.873483+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nektar prices $325M upsized equity offering at $92/share; net proceeds ~$350.9M

## Summary
- Firm shares: 3,532,609 at $92.00; underwriters exercised option for 529,891 additional shares in full.
- Net proceeds estimated at ~$350.9M after underwriting discounts and offering expenses.
- Proceeds to fund general corporate purposes, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata.
- Joint bookrunners include Jefferies, TD Cowen, Piper Sandler; Citigroup also bookrunner.
- Offering expected to close on April 23, 2026.

## SEC filing metadata
- accession: 0001193125-26-171731
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000119312526171731/0001193125-26-171731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000119312526171731/d80358d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-171731
- JSON: https://secwatch.observer/filing/0001193125-26-171731.json
- Plain text: https://secwatch.observer/filing/0001193125-26-171731.txt

## Source-grounded claims
- claim_id: d7eab357ea8a55fb6e02baed7e4d162af7533ec7
  claim: NEKTAR THERAPEUTICS entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. valued at approximately $350.9 million (effective 2026-04-21).
  evidence_excerpt: On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,532,609 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) at a price to the public of $92.00 per Firm Share, less underwriting discounts and commissions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526171731/0001193125-26-171731-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.